CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples